基因融合檢測市場－全球產業規模、佔有率、趨勢、機會和預測：按類別、技術、適應症、最終用戶、地區和競爭格局分類，2021-2031年

全球基因融合檢測市場預計將從 2025 年的 7.1368 億美元大幅成長至 2031 年的 14.5922 億美元，複合年成長率高達 12.66%。

基因融合檢測在分子層面分析生物檢體，以識別染色體重排產生的融合基因。這些基因是指導標靶蛋白酪氨酸激酶抑制劑療法選擇的關鍵生物標記。此市場擴張的主要驅動力是組織非依賴性藥物的核准不斷增加，以及融合陽性固體癌（尤其是非小細胞肺癌）發生率的上升。

精準的基因組鑑定對於輔助治療決策具有極高的臨床需求，例如，預計到2025年美國將新增226,650例肺癌病例，凸顯了此類診斷方法的緊迫性。儘管其臨床效益顯而易見，但缺乏統一的綜合基因組分析保險報銷系統仍然是市場發展的主要障礙。針對不同基因組的次世代定序，保險覆蓋範圍的差異往往會造成經濟負擔，限制患者獲得這些必要的診斷工具，並阻礙其在各種醫療環境中的廣泛商業性應用。

市場促進因素

全球基因融合檢測市場的主要驅動力是次世代定序(NGS) 和分子診斷技術的持續進步，這些技術如今能夠同時識別多種具有治療意義的基因組突變。現代 NGS 平台已從單基因分析發展到提供全面的基因組分析，顯著提高了檢測涉及 NTRK、ROS1 和 ALK 等基因的罕見融合事件所需的靈敏度。這些技術進步正日益受到監管機構的核准。例如，FDA 於 2025 年 1 月核准了FoundationOne CDx，用於識別 BRAF 融合和重排，從而促進兒童標靶治療。主要產業參與者的商業性支持也推動了市場成長；Illumina 公司公佈，2025 年第三季銷售額達 10.8 億美元，部分原因是其臨床定序部門的加速成長。

此外，全球範圍內符合標靶治療條件的癌症發生率不斷上升，顯著推動了對精準基因融合檢測的需求。隨著癌症負擔在全球範圍內持續加重，醫療系統日益重視識別特定的基因組促進因素，以透過個人化醫療方法改善治療效果。美國癌症協會預測，到2025年，美國將新增2,041,910例癌症病例，這意味著大量患者可能成為基因組篩檢的目標族群。鑑於癌症發生率的不斷上升，亟需廣泛應用融合基因特異性診斷技術，以精準指導蛋白酪氨酸激酶抑制劑的使用，確保基因融合檢測在現代癌症治療中繼續發揮關鍵作用。

市場挑戰

全球基因融合檢測市場商業性擴張的一大障礙是全面基因組分析的報銷環境高度不穩定。當保險公司實施不一致的福利政策或拒絕支付廣泛的基因組定序費用時，臨床檢查室將面臨收入不確定性和財務不穩定。這種不穩定的經濟環境是醫療機構不願採用先進的融合檢測方法的主要原因，因為這些方法無法保證能夠獲得足夠的投資回報，以彌補與次世代定序相關的巨額營運投入。因此，醫療機構往往選擇檢測範圍更窄、成本效益更高的檢測方法，這直接限制了整體市場規模，並阻礙了這些關鍵診斷方法在常規臨床實踐中的標準化應用。

聯邦政府的報銷調整進一步加劇了這些挑戰，例如美國病理學家學會 (CAP) 計劃於 2025 年實施的病理檢測服務報銷額度下調 2.5%。這些調整給診斷服務提供者帶來了更大的財務壓力。報銷率的降低嚴重限制了檢查室承擔拒付索賠成本和維持盈利的能力。由於醫療機構在應對報銷額度降低和保險障礙的雙重挑戰的同時，基因融合檢測的普及和廣泛應用將受到限制，最終阻礙該領域的經濟成長，並限制患者獲得先進的精準腫瘤治療的機會。

市場趨勢

液態生物檢體的出現，標誌著非侵入性融合基因檢測市場的變革性轉變，有效克服了傳統切片檢查程序中組織樣本獲取的重大限制。與難以重複的侵入性固態腫瘤取樣不同，利用血漿進行次世代定序，只需簡單的抽血即可實現融合基因狀態的連續和時間序列監測，並檢測抗藥性機制。這種以患者為中心的檢測方法正在臨床實踐中迅速普及，使醫療機構能夠在保持高診斷準確率的同時，避免組織取樣帶來的許多後勤障礙。例如，佛羅裡達癌症專科醫師與研究中心報告稱，到2025年6月，該中心將處理超過16,000例分子檢測，而這些微創檢測方法的引入顯著加快了這一里程碑的實現。

同時，人工智慧 (AI) 的整合應用正在革新複雜基因組數據的解讀方式，尤其是在準確識別罕見和隱匿的基因融合方面。隨著定序panel日益全面，產生的數據量龐大，常常令傳統的生物資訊流程不堪重負，可能導致假陰性和誤判。 AI演算法能夠以更高的準確性和效率區分真正的融合事件和定序偽影，從而有效緩解這一問題。這項技術飛躍有效地彌合了原始數據與可操作的臨床見解之間的鴻溝。新加坡基因解決方案公司 (Gene Solutions Singapore) 於2025年12月發布的公告印證了這一點，該公司展示的基因融合檢測率較標準分析方法提高了20%，顯著提升了診斷能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球基因融合檢測市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類別（調查、診斷）
  • 透過技術（次世代定序（NGS）、螢光雜合反應（FISH）、聚合酵素鏈鎖反應（PCR）、免疫組織化學（IHC））
  • 適應症（固體癌、骨髓惡性腫瘤）
  • 按最終用戶分類（製藥和生物技術公司、醫院和診斷檢測實驗室、學術和研究機構）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美基因融合檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲基因融合檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區基因融合檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲基因融合檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲基因融合檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球基因融合檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN NV
• Amoy Diagnostics Co., Ltd.
• ArcherDX（Integrated DNA Technologies, Inc.）
• Biocartis
• Biocare Medical, LLC
• Guardant Health, Inc.
• Myriad Genetics, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Gene Fusion Testing Market is projected to expand significantly, from USD 713.68 Million in 2025 to USD 1459.22 Million by 2031, demonstrating a robust Compound Annual Growth Rate (CAGR) of 12.66%. Gene fusion testing involves the molecular examination of biological samples to pinpoint hybrid genes resulting from chromosomal rearrangements, which are crucial biomarkers for guiding the selection of targeted tyrosine kinase inhibitor therapies. This market expansion is primarily fueled by the increasing approvals of tissue-agnostic drugs and the rising prevalence of fusion-positive solid tumors, notably non-small cell lung cancer.

The substantial clinical demand for precise genomic identification to inform therapeutic decisions is underscored by projections such as the estimated 226,650 new lung cancer cases in the United States in 2025, highlighting the critical need for these diagnostics. Despite the clear clinical benefits, a significant hurdle for the market remains the inconsistent reimbursement landscape for comprehensive genomic profiling. Variable insurance coverage policies for broad-panel next-generation sequencing often create financial obstacles, limiting patient access to these essential diagnostic tools and thereby impeding their wider commercial adoption across diverse healthcare environments.

Market Driver

The primary catalyst for the Global Gene Fusion Testing Market is the continuous technological advancement in next-generation sequencing (NGS) and molecular diagnostics, which now enables the simultaneous identification of multiple actionable genomic alterations. Modern NGS platforms have evolved from analyzing single genes to offering comprehensive genomic profiling, significantly boosting the sensitivity required to detect even rare fusion events involving genes such as NTRK, ROS1, and ALK. This technical progress is increasingly validated by regulatory bodies, exemplified by the FDA's January 2025 approval of FoundationOne CDx for identifying BRAF fusions and rearrangements to facilitate targeted pediatric therapies, and is commercially supported by major industry players, with Illumina reporting $1.08 billion in quarterly revenue in Q3 2025, partly driven by accelerated growth in its clinical sequencing segment.

Furthermore, the escalating global incidence of targetable cancer indications significantly propels the demand for precise gene fusion testing. As the burden of oncological diseases worldwide continues to rise, healthcare systems are increasingly prioritizing the identification of specific genomic drivers to enhance treatment efficacy through personalized medicine approaches. The American Cancer Society projected 2,041,910 new cancer cases in the United States in 2025, representing a substantial patient cohort potentially eligible for genomic screening. This growing prevalence necessitates the widespread implementation of fusion-specific diagnostics to accurately guide the administration of tyrosine kinase inhibitors, ensuring gene fusion testing remains an indispensable element within the contemporary oncological care continuum.

Market Challenge

The primary impediment to the commercial expansion of the global gene fusion testing market is the highly variable reimbursement landscape for comprehensive genomic profiling. When payers implement inconsistent coverage policies or deny claims for broad-panel sequencing, clinical laboratories face considerable revenue uncertainty and financial instability. This precarious economic environment actively discourages medical facilities from adopting advanced fusion detection assays, as they cannot guarantee a sufficient return on the significant operational investments associated with next-generation sequencing. Consequently, healthcare providers frequently opt for narrower, more cost-effective testing methods, which directly constrains the overall market volume and hinders the standardization of these crucial diagnostics in routine clinical practice.

Further exacerbating these challenges, federal fee schedule adjustments, such as the estimated 2.5 percent payment reduction for pathology services implemented in 2025 by the College of American Pathologists, intensify the economic pressure on diagnostic providers. This contraction in reimbursement rates severely limits laboratories' capacity to absorb the costs of denied claims and maintain profitability. As facilities struggle to navigate declining payments alongside unpredictable insurance barriers, the accessibility and widespread deployment of gene fusion testing are curtailed, ultimately impeding the sector's financial growth and limiting patient access to advanced precision oncology.

Market Trends

The emergence of liquid biopsy for non-invasive fusion detection represents a transformative shift within the market, effectively overcoming the critical limitation of tissue availability inherent in conventional biopsy procedures. Unlike invasive solid tumor sampling, which can be difficult to repeat, plasma-based next-generation sequencing allows for continuous, longitudinal monitoring of fusion status and the detection of resistance mechanisms through a simple blood draw. This patient-centric method is rapidly gaining widespread traction in clinical settings, enabling providers to bypass significant logistical hurdles associated with tissue acquisition while simultaneously maintaining high diagnostic precision. Florida Cancer Specialists & Research Institute, for instance, reported processing over 16,000 molecular tests by June 2025, a milestone significantly accelerated by the integration of these minimally invasive assay options.

Concurrently, the integration of artificial intelligence (AI) for enhanced bioinformatics analysis is revolutionizing the interpretation of complex genomic data, particularly for accurately identifying rare and cryptic gene fusions. As sequencing panels become more comprehensive, the sheer volume of data generated frequently overwhelms traditional bioinformatic pipelines, potentially leading to false negatives or misinterpretations; AI algorithms effectively mitigate this by distinguishing true fusion events from sequencing artifacts with superior accuracy and efficiency. This technological leap effectively bridges the gap between raw genomic output and actionable clinical insights, exemplified by Gene Solutions Singapore's December 2025 announcement that its proprietary AI-driven platform improved gene fusion detection rates by 20 percent compared to standard analytical methods, thus enhancing diagnostic capabilities.

Key Market Players

• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN N.V.
• Amoy Diagnostics Co., Ltd.
• ArcherDX (Integrated DNA Technologies, Inc.)
• Biocartis
• Biocare Medical, LLC
• Guardant Health, Inc.
• Myriad Genetics, Inc.

Report Scope

In this report, the Global Gene Fusion Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Fusion Testing Market, By Category

• Research
• Diagnostic

Gene Fusion Testing Market, By Technology

• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Polymerase Chain Reaction (PCR)
• Immunohistochemistry (IHC)

Gene Fusion Testing Market, By Indication

• Solid Tumors
• Hematological Malignancies

Gene Fusion Testing Market, By End User

• Pharmaceutical and Biotechnology Companies
• Hospitals and Diagnostic Laboratories
• Academic & Research Centers

Gene Fusion Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Fusion Testing Market.

Available Customizations:

Global Gene Fusion Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Fusion Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Category (Research, Diagnostic)
  • 5.2.2. By Technology (Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC))
  • 5.2.3. By Indication (Solid Tumors, Hematological Malignancies)
  • 5.2.4. By End User (Pharmaceutical and Biotechnology Companies, Hospitals and Diagnostic Laboratories, Academic & Research Centers)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Gene Fusion Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Category
  • 6.2.2. By Technology
  • 6.2.3. By Indication
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gene Fusion Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Category
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Gene Fusion Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Category
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Gene Fusion Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Category
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By End User

7. Europe Gene Fusion Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Category
  • 7.2.2. By Technology
  • 7.2.3. By Indication
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gene Fusion Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Category
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By End User
  • 7.3.2. France Gene Fusion Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Category
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Gene Fusion Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Category
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Gene Fusion Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Category
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Gene Fusion Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Category
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By End User

8. Asia Pacific Gene Fusion Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Category
  • 8.2.2. By Technology
  • 8.2.3. By Indication
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gene Fusion Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Category
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By End User
  • 8.3.2. India Gene Fusion Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Category
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Gene Fusion Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Category
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Gene Fusion Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Category
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Gene Fusion Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Category
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By End User

9. Middle East & Africa Gene Fusion Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Category
  • 9.2.2. By Technology
  • 9.2.3. By Indication
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gene Fusion Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Category
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Gene Fusion Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Category
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Gene Fusion Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Category
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By End User

10. South America Gene Fusion Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Category
  • 10.2.2. By Technology
  • 10.2.3. By Indication
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gene Fusion Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Category
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Gene Fusion Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Category
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Gene Fusion Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Category
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gene Fusion Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina, Inc.
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. QIAGEN N.V.
• 15.5. Amoy Diagnostics Co., Ltd.
• 15.6. ArcherDX (Integrated DNA Technologies, Inc.)
• 15.7. Biocartis
• 15.8. Biocare Medical, LLC
• 15.9. Guardant Health, Inc.
• 15.10. Myriad Genetics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer